Frequency Therapeutics, a company developing a pipeline of drugs by activating progenitor cells within the body, has announced the appointment of John LaMattina, Ph.D. as a senior advisor to the CEO, and a member of the scientific advisory board.
“As a highly-regarded industry veteran, John brings us a wealth of knowledge and expertise,” said David Lucchino, president, co-founder and CEO of Frequency. “John has already begun to help us accelerate the development of our pipeline of product candidates for hearing restoration.”
Dr. LaMattina previously was president of Pfizer Global Research and Development and senior vice president of Pfizer. During Dr. LaMattina’s leadership tenure, Pfizer discovered and developed several important new medicines including Tarceva, Chantix, Zoloft (PTSD), Selzentry and Lyrica along with a number of other medicines currently in late stage development for cancer, rheumatoid arthritis and pain. Dr. LaMattina is the author of numerous scientific publications and U.S. patents, and is the author of “Drug Truths: Dispelling the Myths About Pharma R&D.” He currently serves as an independent non-executive director at PureTech Health.
“It is my pleasure to join Frequency Therapeutics as it begins clinical development of a treatment for hearing loss,” said Dr. LaMattina. “The team has made remarkably rapid progress, and Frequency’s Progenitor Cell Activation platform presents an exceptional opportunity to develop a wide range of new disease-modifying therapies for hearing and other areas throughout the body.”